Carol Farhangfar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carol Farhangfar has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Joel R. Eisner
GeneCentric Therapeutics, Inc., Durham, North Carolina
54 shared publications - Kirk D. Beebe
GeneCentric Therapeutics, Inc., Durham, North Carolina
54 shared publications - Yuelong Guo
GeneCentric Therapeutics, Inc., Durham, North Carolina
54 shared publications - Kathryn F. Mileham
Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC
51 shared publications - Farhang Farhangfar
Levine Cancer Institute, Atrium Health , Charlotte, NC
48 shared publications - James M. Davison
GeneCentric Therapeutics, Inc., Durham, North Carolina
48 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Worldwide Innovative Network Consortium: Building a Common Global Cancer Database
This review shares the ongoing work of the global Worldwide Innovative Network (WIN) Consortium for Precision Medicine to synthesize emerging cancer treatment data and to define the requirements for a common global cancer database that can truly support precision oncology. We performed a narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured. The growth in molecular profiling technologies and the development of new targeted therapies are transforming cancer care. Tumors, regardless of tissue origin, are increasingly defined as composites of multiple, often rare, subgroups, each with distinct biology and likely response to specific therapies, based on multidimensional profiling of the tumor and its microenvironment. The solution lies in building vast databases that capture racial and ethnic diversity, reflected in genomic data, as well as diet and lifestyle factors that may have epigenetic impact on gene expression and post-translational modifications. A truly inclusive and informative data set must reflect global diversity, and there are multiple examples of demography-dependent differences in genomic signals. With members caring for and studying patients with cancer across five continents, WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence–driven insights, provided appropriate data quality, validation, and governance frameworks are in place. This review surveys the current landscape and outlines practical paths forward to achieve this goal.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Open AccessWorldwide Innovative Network Consortium: Building a Common Global Cancer Database
This review shares the ongoing work of the global Worldwide Innovative Network (WIN) Consortium for Precision Medicine to synthesize emerging cancer treatment data and to define the requirements for a common global cancer database that can truly support precision oncology. We performed a narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured. The growth in molecular profiling technologies and the development of new targeted therapies are transforming cancer care. Tumors, regardless of tissue origin, are increasingly defined as composites of multiple, often rare, subgroups, each with distinct biology and likely response to specific therapies, based on multidimensional profiling of the tumor and its microenvironment. The solution lies in building vast databases that capture racial and ethnic diversity, reflected in genomic data, as well as diet and lifestyle factors that may have epigenetic impact on gene expression and post-translational modifications. A truly inclusive and informative data set must reflect global diversity, and there are multiple examples of demography-dependent differences in genomic signals. With members caring for and studying patients with cancer across five continents, WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence–driven insights, provided appropriate data quality, validation, and governance frameworks are in place. This review surveys the current landscape and outlines practical paths forward to achieve this goal.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600076
Expert Validation of an Artificial Intelligence–Enabled Trial Matching Solution Using Real-World Data From Patients With Cancer
PURPOSE: To validate the performance of an AI system (TRIAGE) for cancer trial eligibility screening using real-world longitudinal electronic health records (EHRs), full versioned trial protocols, and expert clinical research coordinator (CRC) adjudication at the trial and criterion levels. METHODS: This retrospective study of records from August 2017 to April 2025 compared the performance of TRIAGE with real-world enrollment and expert eligibility review of a subset of cases. The train set comprised 148 trials and 628 patients with cancer, resulting in 4,094 patient-trial pairs. The test set comprised 26 trials and 198 patients with breast, lung, and pancreatic cancers, resulting in 820 patient-trial pairs. A stratified random sample of 100 patient-trial pairs (83 patients, 21 trials) underwent manual CRC review and adjudication. The primary outcomes were sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for trial-level eligibility and accuracy for criterion-level decisions. Performance evaluations were based on a binary classification: eligible or potentially eligible versus ineligible. RESULTS: At the predefined trial-level decision threshold for eligibility (0.40), the sensitivity was 78.3%, the specificity was 98.5%, the PPV was 92.6%, and the NPV was 94.8%. A lower threshold (0.13) maximized sensitivity (98.7%), while maintaining high specificity at 97.6%, PPV at 91.2%, and NPV at 99.7%. Criterion-level evaluation across 1,770 adjudications showed 93.1% raw agreement, improving to 94.2% after structured readjudication; 10 of 25 (40%) initial CRC discordances were overturned in favor of TRIAGE. CONCLUSION: TRIAGE accurately determined trial-level eligibility from real-world EHR data with high performance and strong criterion-level agreement for oncology protocols. TRIAGE surfaced potential missed enrollment opportunities and supports adjustable trial-level decision thresholds. Prospective studies of TRIAGE implementation into routine research workflows are ongoing.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600076
Expert Validation of an Artificial Intelligence–Enabled Trial Matching Solution Using Real-World Data From Patients With Cancer
PURPOSE: To validate the performance of an AI system (TRIAGE) for cancer trial eligibility screening using real-world longitudinal electronic health records (EHRs), full versioned trial protocols, and expert clinical research coordinator (CRC) adjudication at the trial and criterion levels. METHODS: This retrospective study of records from August 2017 to April 2025 compared the performance of TRIAGE with real-world enrollment and expert eligibility review of a subset of cases. The train set comprised 148 trials and 628 patients with cancer, resulting in 4,094 patient-trial pairs. The test set comprised 26 trials and 198 patients with breast, lung, and pancreatic cancers, resulting in 820 patient-trial pairs. A stratified random sample of 100 patient-trial pairs (83 patients, 21 trials) underwent manual CRC review and adjudication. The primary outcomes were sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for trial-level eligibility and accuracy for criterion-level decisions. Performance evaluations were based on a binary classification: eligible or potentially eligible versus ineligible. RESULTS: At the predefined trial-level decision threshold for eligibility (0.40), the sensitivity was 78.3%, the specificity was 98.5%, the PPV was 92.6%, and the NPV was 94.8%. A lower threshold (0.13) maximized sensitivity (98.7%), while maintaining high specificity at 97.6%, PPV at 91.2%, and NPV at 99.7%. Criterion-level evaluation across 1,770 adjudications showed 93.1% raw agreement, improving to 94.2% after structured readjudication; 10 of 25 (40%) initial CRC discordances were overturned in favor of TRIAGE. CONCLUSION: TRIAGE accurately determined trial-level eligibility from real-world EHR data with high performance and strong criterion-level agreement for oncology protocols. TRIAGE surfaced potential missed enrollment opportunities and supports adjustable trial-level decision thresholds. Prospective studies of TRIAGE implementation into routine research workflows are ongoing.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
RNA Sequencing Quality Control Criteria
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
RNA Sequencing Quality Control Criteria
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Expression of Genes Associated with Antifolate (Pemetrexed) Activity by LUAD Subtype.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Expression of Genes Associated with Antifolate (Pemetrexed) Activity by LUAD Subtype.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Relationship of the expression of individual genes (ATIC, GART, DHFR, MTHFD1L or TYMS) with survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Relationship of the expression of individual genes (ATIC, GART, DHFR, MTHFD1L or TYMS) with survival.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
48 genes included in the new LUAD nearest centroid classifier and associated AF-PRS signature.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
48 genes included in the new LUAD nearest centroid classifier and associated AF-PRS signature.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Development of the 48-gene LUAD nearest centroid classifier
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Development of the 48-gene LUAD nearest centroid classifier
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Expression Matrix of Patient Tumor Sample RNAseq
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Expression Matrix of Patient Tumor Sample RNAseq
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Purpose:The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non–small cell lung cancer (NSCLC) treated with pemetrexed-containing platinum doublet chemotherapy (PMX-PDC). The study tested the hypothesis that AF-PRS identifies patients with NS-NSCLC who have a higher likelihood of responding positively to PMX-PDC. The goal was to gather clinical evidence supporting AF-PRS as a potential diagnostic test.Experimental Design:Residual pretreatment FFPE tumor samples and clinical data were analyzed from 105 patients treated with first-line (1L) PMX-PDC. Ninety-five patients had sufficient RNA sequencing (RNA-seq) data quality and clinical annotation for inclusion in the analysis. Associations between AF-PRS status and associate genes and outcome measures including progression-free survival (PFS) and clinical response were evaluated.Results:Overall, 53% of patients were AF-PRS(+), which was associated with extended PFS, but not overall survival, versus AF-PRS(−) (16.6 months vs. 6.6 months; P = 0.025). In patients who were stage I to III patients at the time of treatment, PFS was further extended in AF-PRS(+) versus AF-PRS(−) (36.2 months vs. 9.3 months; P = 0.03). Complete response (CR) to therapy was noted in 14 of 95 patients. AF-PRS(+) preferentially selected a majority (79%) of CRs, which were evenly split between patients stage I to III (six of seven) and stage IV (five of seven) at the time of treatment.Conclusions:AF-PRS identified a significant population of patients with extended PFS and/or clinical response following PMX-PDC treatment. AF-PRS may be a useful diagnostic test for patients indicated for systemic chemotherapy, especially when determining the optimal PDC regimen for locally advanced disease.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Purpose:The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non–small cell lung cancer (NSCLC) treated with pemetrexed-containing platinum doublet chemotherapy (PMX-PDC). The study tested the hypothesis that AF-PRS identifies patients with NS-NSCLC who have a higher likelihood of responding positively to PMX-PDC. The goal was to gather clinical evidence supporting AF-PRS as a potential diagnostic test.Experimental Design:Residual pretreatment FFPE tumor samples and clinical data were analyzed from 105 patients treated with first-line (1L) PMX-PDC. Ninety-five patients had sufficient RNA sequencing (RNA-seq) data quality and clinical annotation for inclusion in the analysis. Associations between AF-PRS status and associate genes and outcome measures including progression-free survival (PFS) and clinical response were evaluated.Results:Overall, 53% of patients were AF-PRS(+), which was associated with extended PFS, but not overall survival, versus AF-PRS(−) (16.6 months vs. 6.6 months; P = 0.025). In patients who were stage I to III patients at the time of treatment, PFS was further extended in AF-PRS(+) versus AF-PRS(−) (36.2 months vs. 9.3 months; P = 0.03). Complete response (CR) to therapy was noted in 14 of 95 patients. AF-PRS(+) preferentially selected a majority (79%) of CRs, which were evenly split between patients stage I to III (six of seven) and stage IV (five of seven) at the time of treatment.Conclusions:AF-PRS identified a significant population of patients with extended PFS and/or clinical response following PMX-PDC treatment. AF-PRS may be a useful diagnostic test for patients indicated for systemic chemotherapy, especially when determining the optimal PDC regimen for locally advanced disease.
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (11) , 1452-1459
Interpretation of Reports and Translation to Community Oncologists: An Overview of Approaches
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (11) , 1452-1459
Interpretation of Reports and Translation to Community Oncologists: An Overview of Approaches